Astegolimab Biosimilar – Anti-IL1RL1 mAb – Research Grade

Introduction

Astegolimab Biosimilar, also known as Anti-IL1RL1 mAb, is a novel therapeutic antibody that has shown promising results in the treatment of various inflammatory diseases. This biosimilar is a research-grade version of the original Astegolimab, which is a monoclonal antibody designed to specifically target the interleukin-1 receptor like 1 (IL1RL1) protein. In this article, we will delve into the structure, activity, and potential applications of Astegolimab Biosimilar in the field of immunotherapy.

Structure of Astegolimab Biosimilar

Astegolimab Biosimilar is a humanized IgG1 monoclonal antibody, which means it is composed of human antibody sequences with a small portion of non-human antibody sequences. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains contain four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL) and one variable domain (VL). The variable domains of Astegolimab Biosimilar are responsible for binding to the IL1RL1 protein, while the constant domains play a role in effector functions.

Activity of Astegolimab Biosimilar

The main target of Astegolimab Biosimilar is the IL1RL1 protein, also known as the interleukin-33 receptor (IL-33R). This protein is a member of the interleukin-1 receptor family and is expressed on various immune cells, including T cells, B cells, and dendritic cells. IL1RL1 is involved in the regulation of immune responses and has been implicated in the pathogenesis of several inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease.

Astegolimab Biosimilar works by binding to IL1RL1 and blocking its interaction with its ligand, IL-33. This prevents the activation of downstream signaling pathways, leading to a decrease in the production of pro-inflammatory cytokines and chemokines. As a result, Astegolimab Biosimilar helps to reduce inflammation and alleviate symptoms associated with inflammatory diseases.

Potential Applications of Astegolimab Biosimilar

Based on its mechanism of action, Astegolimab Biosimilar has the potential to be used in the treatment of various inflammatory diseases. Some of the conditions that may benefit from this biosimilar include:

– Asthma: IL1RL1 has been shown to play a role in the development of asthma, and blocking its activity with Astegolimab Biosimilar may help to reduce airway inflammation and improve lung function.

– Rheumatoid arthritis (RA): IL1RL1 has also been implicated in the pathogenesis of RA, and targeting this protein with Astegolimab Biosimilar may help to reduce joint inflammation and improve symptoms.

– Inflammatory bowel disease (IBD): Studies have shown that IL1RL1 is upregulated in patients with IBD, and blocking its activity with Astegolimab Biosimilar may help to reduce intestinal inflammation and improve disease activity.

– Psoriasis: IL1RL1 has been found to be involved in the development of psoriasis, and Astegolimab Biosimilar may have a role in reducing skin inflammation and improving symptoms in patients with this condition.

Conclusion

In summary, Astegolimab Biosimilar is a promising therapeutic antibody that specifically targets the IL1RL1 protein. Its unique structure and mechanism of action make it a potential treatment option for various inflammatory diseases. Further research and clinical trials are needed to fully understand the efficacy and safety of this biosimilar, but it holds great potential in the field of immunotherapy.

ProteoGenix catalogue number PX-TA1577. For research use only.

Target: Astegolimab Biosimilar – Anti-IL1RL1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Download the manufacturer safety data sheet (MSDS/SDS)